GARS anticorps (AA 43-289)

N° du produit ABIN7596061

L’anticorps Souris Monoclonal anti-GARS a été validé pour WB, IF, ELISA et ICC. Il convient pour détecter GARS dans des échantillons de Humain.

Aperçu rapide pour GARS anticorps (AA 43-289) (ABIN7596061)

Antigène: GARS (Glycyl-tRNA Synthetase (GARS))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp GARS est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), ELISA, Immunocytochemistry (ICC)

Clone: AT4E10

Détail du produit anti-GARS anticorps

Épitope: AA 43-289

Fonction: Human GARS antibody

Purification: protein-A affinity chromatography

Immunogène: Recombinant human GARS (43-289aa) purified from E. coli

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycero

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Can be stored at +2°C to +8°C for 1 week. For long term storage, aliquot and store at -20°C to -80°C. Avoid repeated freezing and thawing cycles.

Détails sur GARS

Antigène: GARS (Glycyl-tRNA Synthetase (GARS))

Autre désignation: GARS

Sujet: GARS, also known as glycyl-tRNA synthetase, is one of the aminoacyl-tRNA synthetase that charge tRNAswith their cognate amino acids. Defects in the gene encoding GlyRS is the cause of Charcot-Marie-Toothdisease type 2D (CMT2D), which is an autosomal dominant inherited disease characterized by severe weakness,atrophy and absence of deep tendon reflexes in the upper extremities. Defects in the GlyRS gene is also thecause of distal hereditary muscular neuropathy type V (HMN5), a disease similar to CMT2D, though the distalsensory involvement is less severe in HMN5 patients.

NCBI Accession: NP_002038

Pathways: Ribonucleoside Biosynthetic Process